US bankrolls a third of global Pandemic Fund. Can it get congressional support?
The US Treasury has committed $667 million for a global Pandemic Fund hosted by the World Bank, a third of the $2 billion the fund hopes to raise. There’s just one hurdle: A divided Congress has to...
View ArticleRepublican-led states can't intervene in case on abortion pill restrictions,...
A federal appeals court has unanimously rejected an attempt by a group of Republican states to intervene in a lawsuit seeking fewer restrictions for the abortion pill mifepristone. Mifepristone is...
View ArticleViking to push obesity drug to Phase 3 in bid to reach market faster
Viking Therapeutics is stepping on the gas with its experimental GLP-1/GIP receptor agonist for obesity, forgoing a Phase 2b study and jumping right into Phase 3, the company announced. Viking declined...
View ArticleArgenx to retest Vyvgart in autoimmune platelet disease after failure last year
The Dutch biotech argenx has big plans to develop its drug Vyvgart in more than a dozen autoimmune diseases. But failures in two pivotal studies threw a wrench in that strategy late last year. Now,...
View ArticleIpsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug
In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor treatment tovorafenib to market outside the...
View ArticleExclusive: After selling Mirati to BMS for nearly $5B, Chuck Baum lands at...
Mirati Therapeutics’ longtime leader Charles “Chuck” Baum has taken a new job as CEO of Terremoto Biosciences, a Bay Area biotech that’s developing drugs that can bind permanently to challenging...
View ArticleBioMarin snags expanded Brineura label, now approved for all kids regardless...
The FDA has expanded the approval of BioMarin’s treatment for a genetic neurological condition that spurs seizures and twitching in young children. The agency said Brineura can be used in children of...
View ArticleClik here to view.
Updated: AstraZeneca says there’s ‘very limited’ impact on Farxiga after US...
AstraZeneca has concluded its price negotiations with the IRA for its blockbuster drug Farxiga, in the latest update for pharma companies undergoing the process. Ruud Dobber Ruud Dobber, AstraZeneca’s...
View ArticleClik here to view.
Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs
A year into Roche’s comprehensive portfolio review, the Swiss pharma said it has now taken out 25% of new drug candidates from its pipeline. The ongoing exercise will create room for it to keep...
View ArticleClik here to view.
Sanofi eyes RSV antibody for its next blockbuster while Dupixent brings in...
Sanofi’s RSV antibody Beyfortus is still on track to reach blockbuster status this year as the company expands manufacturing capacity, according to remarks made Thursday morning by Sanofi executives....
View ArticleManatt scoops up health tech experts Christina Farr and Tom Cassels
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Christina Farr, a health tech investor and former journalist, and Tom Cassels, the former CEO of Rock...
View ArticleNovo Nordisk considers another facility; Lonza’s new CEO shares his priorities
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Novo Nordisk has secured land and planning permission in Denmark to...
View ArticleClik here to view.
AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says
AbbVie said Thursday that its highly anticipated acquisition of Cerevel Therapeutics is slated to close soon. It also reported higher-than-anticipated second-quarter revenues. The $8.7 billion deal,...
View ArticleGalderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis
Plus, news about GlycoMimetics and Indivior: Galderma stops plans to develop nemolizumab in Phase 2: The Swiss dermatology company said it will “deprioritize” nemolizumab in advanced chronic kidney...
View ArticleSanofi shelves four assets, including mid-stage dwarfism candidate
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies. The French pharma deprioritized a Phase 2 drug that it was testing to treat...
View ArticleClik here to view.
AstraZeneca details ‘very ambitious’ strategy for early-stage obesity programs
AstraZeneca plans to develop treatment options for people with different BMIs as part of its “very ambitious” obesity strategy. AstraZeneca CEO Pascal Soriot on Thursday detailed the company’s plans,...
View ArticleClik here to view.
AbbVie beats expectations with smaller Humira slide — and big gains for next...
Humira isn’t going anywhere yet. And its successors are coming along nicely, too. On Thursday, AbbVie shared second-quarter financial results that show its cornerstone immunology medication eroded more...
View ArticleClik here to view.
Taking advantage of recent successes, Roche will push obesity drugs faster,...
With GLP-1 drugs taking the pharma world by storm, Roche is attempting to push forward the drugs it acquired in its Carmot Therapeutics acquisition last year a little bit faster. The bid to accelerate...
View ArticleIpsen loses legal appeal over whether blockbuster cancer treatment is a drug...
The pharma company Ipsen has lost the latest round of its legal effort to have its blockbuster cancer product Somatuline Depot classified as a biologic, instead of a drug. Ipsen had sued after the FDA...
View ArticleClik here to view.
EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac...
European regulators are poised to approve Novo Nordisk’s blockbuster drug Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese. The EU’s Committee for Medicinal...
View Article